Join
Live feed
·
PRReleasevia Quantisnow
Nanobiotix S.A. logo

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
NBTX· Nanobiotix S.A.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBTX (Nanobiotix S.A.) and more on Quantisnow.